UL Prospector
Prospector

CelluCap™ RL

  • Company:

    Tagra Biotechnologies Ltd.

  • INCI Name:

    Pentaerythrityl Tetra-di-t-butyl Hydroxyhydrocinnamate (and) Retinol (and) Cellulose Acetate Butyrate (and) Tricaprylin

CelluCap™ RL’s encapsulated Retinol is easily released upon mechanical pressure, such as a rubbing action. The single layer polymeric shell collapses and breaks down into invisible particles, but still retains the payload to continue and deliver over time. Until the moment of application, Retinol remains fresh and potent. Retinol is highly recognized as a very effective vitamin for anti-aging treatment due to its capacity to stimulate collagen production, accelerate cell reproduction and normalize skin keratinization. Its regular application significantly improves skin elasticity, smoothness, and softness, resulting in younger, clearer and healthier looking skin. Nevertheless, Retinol is highly sensitive to oxidation, degradation in the presence of air, sunlight, acidic conditions and heavy metals which results in decreased efficacy and formula discoloration. Tagra Biotechnologies overcomes these challenges with CelluCap™ RL. By delivering stabilized pure Retinol in a microencapsulation, Tagra helps to improve the performance and shelf life of the final formula.

Upgrade to Prospector Premium to view Compliance Highlights Learn More

Retailer Compliance Status

No retailer information is available at this time.

Regulatory & Advisory Status

No regulatory information is available at this time.

Compliance information powered by UL's ChemADVISOR™ Regulatory Database.

Company

Tagra Biotechnologies, since its inception in 1998, focuses on developing and manufacturing microencapsulated ingredients such as actives, pigments, essential oils, UV filters, and highly water-soluble ingredients.

Tagra is the first to patent a unique innovative Release on Demand™ (RND™) Microencapsulation Technology. Tagra’s platform addresses industry challenges of stability, efficiency, and compatibility with other cosmetic and pharmaceutical formulation ingredients. The technology enables the masking, protecting, and releasing of more than 40 actives and pigments widely used in cosmetics and OTC preparations. Tagra’s microcapsules are friction released through consumer applications.

Tagra also owns and operates its own plant and state-of-the-art laboratory meeting all required regulations.

Company Documents

The information presented here was acquired by UL from the producer of the product or material or original information provider. However, UL assumes no responsibility or liability for the accuracy of the information contained on this website and strongly encourages that upon final product or material selection information is validated with the manufacturer. This website provides links to other websites owned by third parties. The content of such third party sites is not within our control, and we cannot and will not take responsibility for the information or content.

Tagra Biotechnologies Ltd. makes their documentation available in the regions indicated below:

Where to Buy

Tagra Biotechnologies Ltd.

Are you a distributor who is interested in being listed here? Contact us!